金域医学(603882) - 2024 Q2 - 季度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders for the first half of 2024 to be between 80 million and 100 million yuan, a decrease of 18.48435 million to 20.48435 million yuan compared to the same period last year, representing a year-on-year decline of 64.89% to 71.91%[2] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 65 million and 85 million yuan, down by 18.75746 million to 20.75746 million yuan year-on-year, reflecting a decline of 68.82% to 76.15%[2] - The total profit for the same period last year was 325.9291 million yuan, with a net profit attributable to shareholders of 284.8435 million yuan[4] - The basic earnings per share for the same period last year was 0.61 yuan[4] Reasons for Profit Reduction - The main reasons for the profit reduction include slower-than-expected growth in routine testing demand, high fixed cost investments, and significant credit impairment losses estimated at approximately 290 million yuan for the first half of 2024[5] Earnings Forecast - The company does not foresee any major uncertainties affecting the accuracy of this earnings forecast[6] - The forecast data is preliminary and subject to change, with the final financial data to be disclosed in the official half-year report[6]